#1 Clinical Trials Search in Europe

Mezigdomide

Mezigdomide, also known as BMS-986348 or CC-92480, is an investigational drug being studied in clinical trials for the treatment of multiple myeloma, a type of blood cancer. This article explores the ongoing research into mezigdomide’s potential as a novel therapy for patients with relapsed or refractory multiple myeloma, either alone or in combination with other drugs.

Table of Contents

What is Mezigdomide?

Mezigdomide is a new drug being developed for the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It is also known by its alternative names BMS-986348 and CC-92480[1][2]. Mezigdomide belongs to a class of drugs called cereblon E3 ligase modulators (CELMoDs), which are designed to enhance the body’s ability to fight cancer cells[4].

How Mezigdomide Works

Mezigdomide works by targeting specific proteins in cancer cells, leading to their destruction. It enhances the body’s natural ability to break down certain proteins that cancer cells need to survive. Specifically, it increases the degradation of proteins called Ikaros and Aiolos, which play a role in the growth of multiple myeloma cells. By targeting these proteins, mezigdomide can cause cancer cells to die and potentially slow down or stop the progression of the disease[4].

Conditions Treated with Mezigdomide

Mezigdomide is primarily being studied for the treatment of multiple myeloma, particularly in patients whose cancer has returned (relapsed) or has not responded well to previous treatments (refractory). The main conditions being investigated include:

  • Relapsed or Refractory Multiple Myeloma (RRMM): This refers to multiple myeloma that has come back after initial treatment or has not responded well to previous therapies[3].
  • Newly Diagnosed Multiple Myeloma (NDMM): Some studies are also looking at the use of mezigdomide in patients who have been recently diagnosed with multiple myeloma[8].

Ongoing Research and Clinical Trials

Mezigdomide is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials are investigating various aspects of the drug, including:

  • Dosage and Administration: Researchers are working to determine the best dose and schedule for taking mezigdomide[1].
  • Drug Interactions: Studies are examining how mezigdomide interacts with other medications and how it’s processed by the body, especially in patients with liver or kidney problems[1][2].
  • Effectiveness: Trials are measuring how well mezigdomide works in treating multiple myeloma, looking at factors like overall response rate, progression-free survival, and overall survival[7].
  • Quality of Life: Some studies are assessing how mezigdomide affects patients’ quality of life during treatment[7].

Mezigdomide in Combination Therapies

Many of the ongoing clinical trials are studying mezigdomide in combination with other drugs. This approach, known as combination therapy, is common in cancer treatment as it can often lead to better results than using a single drug alone. Some of the combinations being studied include:

  • Mezigdomide + Elranatamab: This combination is being studied for relapsed and/or refractory multiple myeloma[3].
  • Mezigdomide + Ixazomib + Dexamethasone: This three-drug combination is being investigated for relapsed and refractory multiple myeloma[4].
  • Mezigdomide + Carfilzomib + Dexamethasone: This combination is being compared to a standard treatment in a large clinical trial[7].
  • Mezigdomide + Bortezomib + Dexamethasone: Another three-drug combination being studied[6].
  • Mezigdomide + Alnuctamab: This combination is being evaluated in early-phase clinical trials[5].

Potential Side Effects and Safety Considerations

As with all medications, mezigdomide may cause side effects. The ongoing clinical trials are carefully monitoring patients for any adverse events. Some of the potential side effects being studied include:

  • Blood-related issues such as low blood cell counts
  • Infections
  • Fatigue
  • Nausea or vomiting
  • Diarrhea
  • Changes in liver or kidney function

It’s important to note that not all patients will experience these side effects, and the severity can vary. The clinical trials are designed to identify the safest and most effective dosage to minimize side effects while maximizing benefits[5][7].

Important Considerations for Patients

If you’re considering participating in a clinical trial involving mezigdomide or if your doctor has suggested it as a potential treatment option, here are some important points to keep in mind:

  • Experimental Nature: Mezigdomide is still an experimental drug and is not yet approved for general use. It’s only available through clinical trials at this time.
  • Close Monitoring: Patients in clinical trials are closely monitored for both effectiveness and side effects. This often involves frequent doctor visits and tests.
  • Combination with Other Treatments: Mezigdomide is often given in combination with other drugs. Make sure you understand all the medications involved in your treatment plan.
  • Individual Response: As with all cancer treatments, the response to mezigdomide can vary from person to person.
  • Informed Consent: If you’re considering a clinical trial, you’ll be provided with detailed information about the study and will need to give informed consent before participating.

Remember, your healthcare team is the best source of information about whether mezigdomide might be appropriate for your specific situation. Always discuss any questions or concerns you have about your treatment options with your doctor[3][4][7].

Aspect Details
Drug Name Mezigdomide (BMS-986348, CC-92480)
Drug Class Cereblon E3 Ligase Modulator (CELMoD)
Condition Studied Relapsed and/or Refractory Multiple Myeloma
Study Phases Phase 1, Phase 2, Phase 3
Combination Therapies Dexamethasone, Carfilzomib, Elranatamab, Alnuctamab, Bortezomib
Primary Outcomes Safety, Tolerability, Maximum Tolerated Dose, Recommended Phase 2 Dose, Overall Response Rate
Secondary Outcomes Progression-free Survival, Overall Survival, Duration of Response, Pharmacokinetics
Administration Oral capsules, various dosing schedules (daily, weekly)
Special Populations Studies in patients with hepatic and renal impairment

FAQ

  • What is mezigdomide? Mezigdomide is an investigational drug being studied for the treatment of multiple myeloma. It is a novel cereblon E3 ligase modulator (CELMoD) that works by enhancing the degradation of certain proteins in cancer cells, potentially leading to their death.
  • How is mezigdomide being studied in clinical trials? Mezigdomide is being studied in various clinical trials, both as a single agent and in combination with other drugs like dexamethasone, carfilzomib, elranatamab, and alnuctamab. These trials aim to determine the safety, efficacy, and optimal dosing of mezigdomide in patients with relapsed or refractory multiple myeloma.
  • What are the potential benefits of mezigdomide? Early clinical trials suggest that mezigdomide may be effective in treating multiple myeloma, particularly in patients who have not responded well to other treatments. It is being studied for its potential to improve overall response rates, progression-free survival, and overall survival in multiple myeloma patients.
  • Are there any side effects associated with mezigdomide? As with all medications, mezigdomide may cause side effects. Clinical trials are ongoing to evaluate its safety profile. Common side effects observed in cancer treatments may include fatigue, nausea, and changes in blood cell counts. Specific side effects for mezigdomide are still being determined through clinical studies.
  • How can patients participate in clinical trials involving mezigdomide? Patients interested in participating in clinical trials involving mezigdomide should consult with their healthcare provider. They can also search for ongoing trials on websites like clinicaltrials.gov and discuss their eligibility with the study coordinators or their oncologist.

Ongoing Clinical Trials on Mezigdomide

  • Study of mezigdomide and elranatamab combination treatment for patients with relapsed or refractory multiple myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Germany Greece Norway Spain

  • Study on the Safety and Effects of CC-92480 with Dexamethasone and Drug Combinations for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1
    Investigated drugs:
    Norway Spain

  • Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Finland France Germany +7

  • A study of belantamab mafodotin and mezigdomide in patients with relapsed multiple myeloma who have previously received CAR-T cell therapy or bispecific antibodies

    Not yet recruiting

    1 1
    Investigated drugs:
    France

  • A study of mezigdomide, carfilzomib, and dexamethasone in patients with relapsed or refractory multiple myeloma.

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Alnuctamab and Mezigdomide for Patients with Relapsed or Refractory Multiple Myeloma

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Denmark

  • Study on the Safety and Effectiveness of Mezigdomide and Dexamethasone for Patients with Relapsed and Refractory Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Spain

  • Study on Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed, Refractory, or Newly Diagnosed Multiple Myeloma

    Not recruiting

    1 1 1
    Investigated drugs:
    Denmark France Germany Greece Italy Spain

  • Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Bulgaria Denmark Germany Greece Hungary +5

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell in the bone marrow. It can lead to bone pain, kidney problems, and weakened immune system.
  • Relapsed Multiple Myeloma: When multiple myeloma returns after a period of remission or response to treatment.
  • Refractory Multiple Myeloma: When multiple myeloma does not respond to treatment or stops responding after initial improvement.
  • Cereblon E3 Ligase Modulator (CELMoD): A type of drug that modifies the activity of cereblon, a protein involved in the degradation of other proteins in cells. In cancer treatment, CELMoDs can help target and destroy cancer cells.
  • Progression-free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Dose-limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug determined in early clinical trials to be appropriate for further testing in larger studies.

References

  1. https://clinicaltrials.gov/study/NCT05707390
  2. https://clinicaltrials.gov/study/NCT06318676
  3. https://clinicaltrials.gov/study/NCT06645678
  4. https://clinicaltrials.gov/study/NCT06050512
  5. https://clinicaltrials.gov/study/NCT06163898
  6. https://clinicaltrials.gov/study/NCT05519085
  7. https://clinicaltrials.gov/study/NCT05552976
  8. https://clinicaltrials.gov/study/NCT02343042